Surgery Websites
Transplant Surgery »  Meet the Team »  Transplant Surgeons »  Peter G. Stock, M.D., Ph.D.

Peter G. Stock, M.D., Ph.D.

Professor of Surgery
Surgical Director, Kidney and Pancreas Transplant Program
Surgical Director, Pediatric Renal Transplant Program
Co-Director, Pancreatic Islet Cell Transplant Program
Program, Director, T32 Training Program in Transplant Surgery


Contact Information

Academic Office
(415) 353-8617
peter.stock@ucsf.edu
Open Popup

Education

  • University of Illinois, Urbana, IL, B.S., Biology, 1974-78
  • University of Illinois, Chicago, IL, M.D., Medicine, 1978-82
  • University of Minnesota, Minneapolis, MN, Ph.D., Surgery, 1985-92

Residencies

  • University of Minnesota, Intern, General Surgery, 1982-83
  • University of Minnesota, Resident, General Surgery, 1983-90

Fellowships

  • University of California, San Francisco, Fellow, Transplant Surgery, 1990-92

Board Certifications

  • American Board of Surgery, 1991

Program Affiliations

Clinical Expertise

  • Bile Duct Injuries
  • Bile Duct Strictures
  • Cholangiocarcinoma (Bile Duct Cancer)
  • Choledochal Cyst Disease
  • Dialysis Access
  • End-Stage Kidney Disease
  • Fulminant Hepatic Failure
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma (Liver Cancer)
  • Kidney and LIver Transplantation in HIV Patients
  • Kidney Transplantation
  • Liver Transplantation
  • Living Donor Kidney Transplantation
  • Living Donor Liver Transplantation
  • Pancreas Transplantation
  • Pancreatic Islet Cell Transplantation
  • Pediatric Kidney Transplantation
  • Pediatric Liver Transplantation
  • Polycystic Kidney Disease
  • Polycystic Liver Disease
  • Portal Hypertension

Research Interests

  • Induction of transplantation tolerance to block alloimmunity and recurrent autoimmunity following pancreatic islet transplantation
  • Safety and efficacy of solid organ transplantation in people with HIV

Biography

Peter G. Stock, M.D., Ph.D. is Professor of Surgery at UCSF, Surgical Director of the Pediatric Renal Transplantation Program and Surgical Director of the Pancreas Transplant Program. He was trained at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992. Dr. Stock specializes in liver, kidney and pancreas transplantation.

For many years, Dr. Stock was Chair of the Department of Surgery Research Committee. Under his  outstanding leadership. he has helped to establish UCSF Surgery as one of the top research programs for surgical residents in the U.S.

A clincial investigation on which Dr. Stock served as principal investigator led the passage of the Hope Act lifting the ban on research for transplanting organs between HIV-positive donors and recipients.

Dr. Stock is a frequent presenter on issues related to transplantation and immunosuppression, and holds membership in numerous professional and honorary societies.

Awards & Honors

  • James IVth Fellowship Award, US Representative, 2000
  • Faculty Fellowship Award, American College of Surgeons, 1993
  • Sandoz Fellowship Award, American Society of Transplant Surgeons, 1991
  • Outstanding Surgical Resident Teaching Award, Department of Surgery, University of Minnesota, Minneapolis, MN, 1989
  • David Gaviser Award, Outstanding Surgical Research, University of Minnesota, Minneapolis, MN, 1989
  • Outstanding Research Award, Senior Medical Student, University of Illinois, Chicago, IL, 1982
  • Alpha Omega Alpha, University of Illinois, Chicago, IL, 1981
  • Magna Cum Laude, Honors in Biology with High Distinction, University of Illinois, Urbana, IL, 1978
  • Phi Beta Kappa, University of Illinois, Urbana, IL, 1978
View all

Research Overview

Pancreatic Islet Transplantation
The translational research in the field of pancreatic islets revolves around clinical trials of the safety and efficacy of islet transplantation in patients with Type I diabetes. The clinical trials are funded by the National Institutes of Health (NIH) and the Juvenile Diabetes Research Foundation (JDRF). These clinical trials focus on novel immunosuppressive strategies that utilize co-stimulatory blockade to prevent the immune response against pancreatic islets with a regimen that is not toxic to kidneys or beta cells.

Related research involves improving the techniques required for isolating pancreatic islets from the pancreas, which is being conducted in a fully compliant GMP laboratory facility. The study of the alloimmune and autoimmune response following islet transplantation will be conducted to determine the efficacy of the immunosuppressive strategies. Further translational studies will include methods of expanding the source of beta cells, using direct proliferation, as well as manipulation of precursor cells localized in the adult pancreas. We are currently funded (PI) for a translational grant from California Institute of Regenerative Medicine (CIRM) to bring embryonic stem cell-derived beta cells to a clinical trial.

Solid Organ Transplantation in People with HIV
With the advent of highly active anti-retroviral therapy (HAART), HIV has been a chronic disease. People with HIV are no longer dying from progression of HIV to AIDS, but rather as a result of end stage live disease (viral hepatitis co-infection) and kidney disease (HIV nephropathy). Our laboratory heads up the large NIH-sponsored national multicenter trial which is studying the safety and efficacy of solid organ transplantation in people with HIV. Translational research is exploring the impact of HIV on organ function and the impact of immunosuppression on the immune response against HIV and associated copathogens.

Videos

Research Pathways

Featured Publications

From a total of 224 publications
  1. Harbell J, Fung J, Nissen N, Olthoff K, Florman SS, Hanto DW, Light J, Bartlett ST, Tzakis AG, Pearson TC, Barin B, Roland ME, Stock PG. Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients. Surgery. 2012 Sep; 152(3):376-81. View in PubMed
  2. Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME, Terrault NA. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010 May; 10(5):1268-75. View in PubMed
  3. Posselt AM, Szot GL, Frassetto LA, Masharani U, Stock PG. Clinical islet transplantation at the University of California, San Francisco. Clin Transpl. 2010; 235-43. View in PubMed
  4. Blumberg EA, Stock P. Solid organ transplantation in the HIV-infected patient. Am J Transplant. 2009 Dec; 9 Suppl 4:S131-5. View in PubMed
  5. Frassetto LA, Tan-Tam C, Stock PG. Renal transplantation in patients with HIV. Nat Rev Nephrol. 2009 Oct; 5(10):582-9. View in PubMed
  6. Stock PG, Fung J. Viable strategies to facilitate liver transplantation for human immunodeficiency virus coinfection. Liver Transpl. 2009 Sep; 15(9):1003-6. View in PubMed
  7. Stock PG. Balancing multiple and conflicting allocation goals: a logical path forward. Am J Transplant. 2009 Jul; 9(7):1519-22. View in PubMed
  8. Gasser O, Bihl F, Sanghavi S, Rinaldo C, Rowe D, Hess C, Stablein D, Roland M, Stock P, Brander C. Treatment-dependent loss of polyfunctional CD8+ T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation. Am J Transplant. 2009 Apr; 9(4):794-803. View in PubMed
  9. Markmann JF, Kaufman DB, Ricordi C, Schwab PM, Stock PG. Financial issues constraining the use of pancreata recovered for islet transplantation: a white paper. Am J Transplant. 2008 Aug; 8(8):1588-92. View in PubMed
  10. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, Freise CE, Benet LZ, Ascher NL, Roberts JP, Murphy B, Keller MJ, Olthoff KM, Blumberg EA, Brayman KL, Bartlett ST, Davis CE, McCune JM, Bredt BM, Stablein DM, Stock PG. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008 Feb; 8(2):355-65. View in PubMed
  11. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, Carlson L, Benet LZ. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007 Dec; 7(12):2816-20. View in PubMed
  12. Nissen NN, Barin B, Stock PG. Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol. 2012 Sep; 24(5):517-21. View in PubMed
  13. Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl. 2006 May; 12(5):801-7. View in PubMed
  14. Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant. 2006 Apr; 6(4):753-60. View in PubMed
  15. Stock PG. Rapid deterioration of HIV co-infected patients waiting for liver transplantation is not predicted by MELD. Liver Transpl. 2005 Nov; 11(11):1315-7. View in PubMed
  16. Vulchev A, Roberts JP, Stock PG. Ethical issues in split versus whole liver transplantation. Am J Transplant. 2004 Nov; 4(11):1737-40. View in PubMed
  17. Stock PG, Bluestone JA. Beta-cell replacement for type I diabetes. Annu Rev Med. 2004; 55:133-56. View in PubMed
  18. Kang SM, Braat D, Schneider DB, O'Rourke RW, Lin Z, Ascher NL, Dichek DA, Baekkeskov S, Stock PG. A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation. 2000 May 15; 69(9):1813-7. View in PubMed
  19. Kang SM, Hoffmann A, Le D, Springer ML, Stock PG, Blau HM. Immune response and myoblasts that express Fas ligand. Science. 1997 Nov 14; 278(5341):1322-4. View in PubMed
  20. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997 Jul; 3(7):738-43. View in PubMed
  21. Stock PG, Ascher NL, Chen S, Field J, Bach FH, Sutherland DE. Evidence for direct and indirect pathways in the generation of the alloimmune response against pancreatic islets. Transplantation. 1991 Oct; 52(4):704-9. View in PubMed
  22. Stock PG, Ascher NL, Platt JL, Kaufman DB, Chen S, Field MJ, Sutherland DE. Effect of immunodepletion of MHC class II-positive cells from pancreatic islets on generation of cytotoxic T-lymphocytes in mixed islet-lymphocyte coculture. Diabetes. 1989 Jan; 38 Suppl 1:157-60. View in PubMed
  23. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Millis JM, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odim J, Fox L, Stock PG. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012 Jun; 18(6):716-26. View in PubMed
  24. Stock PG, Meloche M, Ascher NL, Chen S, Bach FH, Sutherland DE. Generation of allospecific cytolytic T-lymphocytes stimulated by pure pancreatic beta-cells in absence of Ia+ dendritic cells. Diabetes. 1989 Jan; 38 Suppl 1:161-4. View in PubMed
  25. Vu LT, Baxter-Lowe LA, Garcia J, McEnhill M, Summers P, Hirose R, Lee M, Stock PG. HLA-DR matching in organ allocation: balance between waiting time and rejection in pediatric kidney transplantation. Arch Surg. 2011 Jul; 146(7):824-9. View in PubMed
  26. Stock P, Kirk AD. The risk and opportunity of homeostatic repopulation. Am J Transplant. 2011 Jul; 11(7):1349-50. View in PubMed
  27. Reich DJ, Magee JC, Gifford K, Merion RM, Roberts JP, Klintmalm GB, Stock PG. Transplant surgery fellow perceptions about training and the ensuing job market-are the right number of surgeons being trained? Am J Transplant. 2011 Feb; 11(2):253-60. View in PubMed
  28. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601. View in PubMed
  29. Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18; 363(21):2004-14. View in PubMed
  30. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010 Aug; 10(8):1870-80. View in PubMed
  1. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Peter G. Stock, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

In the News

  • Diverse Group of Researchers Help Pioneer Novel Approach to Treating Type 1 Diabetes Using Pancreatic Islets and Parathyroid Gland Co-Transplantation

    UCSF News Services - Shelley Wong - June 13, 2019
    Researcher of the Month: Peter Stock, MD, PhD As a pivotal figure in HIV-to-HIV organ transplantation and its legalization through the passage of the HIV Organ Policy Equity (HOPE) Act, transplant surgeon Peter G. Stock, MD., PhD., continues to strive toward breakthroughs in research. While Stock is mostly known for his HIV transplantation work, he has been investigating pancreatic islet transplantation (also known as beta cell replacement) to cure type 1 diabetes since his days as a PhD [...]

  • California Institute for Regenerative Medicine Awards Dr. Peter Stock $11M Grant to Conduct Clinical Trial for Treatment of Type 1 Diabetes

    Stem Cellar, The Official Blog of CIRM, California's Stem Cell Agency - Yimy Villa - May 23, 2019
    The California Institute for Regenerative Medicine (CIRM) awarded $11.08 Million to Dr. Peter Stock at the University of California San Francisco (UCSF) to conduct a clinical trial for treatment of Type 1 Diabetes (T1D)... The trial will be using parathyroid glands to aid in the success and viability of the transplant procedure.  Co-transplantation of islets and parathyroid glands, from the same donor, substantially increases beta cell survival, potentially enabling adequate long-term [...]

  • Department of Surgery Ranks 3rd Nationally in NIH Funding for Surgery Category - Three Surgeon-Scientists Rank in Top 20

    UCSF Department of Surgery - Richard Barg - March 27, 2018
    The UCSF Department of Surgery now ranks No. 3 nationally in NIH research funding among all academic surgery programs, a stunning rise from 6th the last time the survey was done. Three Department of Surgery faculty also ranked in the top 20 of all NIH-funded principal investigators nationally in the category of surgery. The highly respected Blue Ridge Institute for Medical Research utilized data from the Research Portfolio Online Reporting Tool (RePORT) to survey U.S. medical schools for their [...]

  • Transplant Surgeons Sandy Feng and Peter Stock Rank in Top 20 of NIH-Funded Investigators in Surgery for 2017

    UCSF Department of Surgery - Richard Barg - March 12, 2018
    Transplant surgeons Sandy Feng, M.D., Ph.D. and Peter G. Stock, M.D., Ph.D. continued their stellar records of accomplishment in garnering NIH funding for their cutting-edge clinical research, ranking in the top 20 of all NIH-Funded principal investigators in the category of surgery nationally for 2017. Stock ranked 8th and Feng 20th out of 534 investigators nationwide, both in the top 4%, this according to survey data analyzed by the highly respected Blue Ridge Institute for Medical Research. [...]

  • Moving Mountains - A Surgeon’s Fight to Legalize HIV-to-HIV Organ Transplants

    UCSF Transplant Surgery - Richard Barg - June 26, 2017
    President Barack Obama signs the HOPE Act legislation in November 2013. Peter Stock (far left) had earlier testified before Congress in support of the legislation, which overturned a federal ban on HIV-to-HIV transplants. Photo by Evan Vucci UCSF News reports on the epic battle, led by UCSF transplant surgeon Peter G. Stock, M.D., Ph.D., to repeal long-standing federal and state laws banning HIV-to-HIV organ transplantation, this after having served as lead Principal Investigator on [...]

  • NIH Awards Department of Surgery T32 Training Grant for Transplant Surgery

    UCSF Department of Surgery - Richard Barg - January 06, 2017
    The NIH has awarded the UCSF Department of Surgery a T32 training grant, "Filling a Void of Research Training for Transplant Surgeons" (FAVOR). The grant, awarded in August 2016, provides annual funding in the amount of $156,602 for in-depth training of three general surgery residents with an interest in transplant surgery during their two research years, the training to be focused on translational immunology. The program is led by Professors Peter G. Stock, M.D., Ph.D. and Minnie M. Sarwal [...]

  • Transplant Drug Sirolimus May Help Eliminate Lingering HIV infections

    UCSF Transplant Surgery - April 01, 2014
    "Researchers studying the effects of immune suppressant drugs on transplant patients with HIV have made a surprising discovery: A drug intended to hobble the body's defense system may actually help destroy dormant reservoirs of the virus that causes AIDS In a paper published this week in the American Journal of Transplantation, authors found that when a small group of transplant patients received the drug sirolimus, they experienced a two- to threefold drop in HIV levels, whereas patients who [...]

  • Dr. Peter Stock Instrumental in Passage of Bill Lifting Research Ban on HIV Organ Transplants

    UCSF Transplant Surgery - December 05, 2013
    Peter Stock And President Obama
    President Barack Obama signs S. 330: HIV Organ Policy Equity Act during a signing ceremony in the Oval Office, Nov. 21, 2013. (Official White House Photo by Lawrence Jackson) MSNBC reports on President Obama's signing of  a bill that ended a decades-old policy that banned organ donations from one HIV-positive person to another. A clinical trial led by UCSF transplant surgeon Peter G. Stock, M.D., Ph.D. was instrumental to the passage of the Hope Act that lifted the ban. The HIV Organ [...]

  • For Type 1 Diabetes, Islet Transplantation Gains Momentum

    UCSF Transplant Surgery - November 14, 2013
    UCSF News, reporting on the 14th World Congress of the International Pancreas and Islet Transplant Association (IPITA), highlighed improving results in  islet cell transplantation: For the worst cases of type 1 diabetes, islet transplantation already has freed hundreds of people from complete dependence on insulin and from life-threatening consequences of the disease. "However, the procedure still is regarded as experimental by the U.S. Food and Drug Administration (FDA). Islets are [...]

  • Doctor: No problems after Antioch toddler undergoes kidney and liver transplant

    UCSF Transplant Surgery - June 05, 2013
    "The sun wasn't up at 5 o'clock Wednesday morning, but a new day had already dawned for Matthew Ouimet. Matthew, a 2-year-old Antioch boy who had waited 15 months for a life-sustaining kidney and liver transplant, had his new organs. Dr. John Roberts took the lead on the liver transplant, and Dr. Peter Stock, who handled the kidney procedure in a 12-hour surgery that began around 6 p.m. Tuesday, delivered the good news to parents Kristi and Kelly Ouimet and a half-dozen family members who spent [...]

  • UCSF Study Prompts Calls to Repeal Ban on Transplanted Organs from HIV-Positive Donors

    UCSF Transplant Surgery - April 11, 2011
    Last year, a team led by Dr. Peter Stock of UCSF reported on results from a large multicenter study testing the safety and feasibility of transplanting kidneys where both the donor and recipients were infected with HIV, the virus that causes AIDS. The results, reported in the New England Journal of Medicine, showed that the recipients survived nearly as long as non-HIV infected recipients of kidney transplants. As a result of the Stock-led trial, and a just-published paper from Johns Hopkins [...]

  • UCSF Liver Transplant Team Shares Expertise in Latin America

    UCSF Transplant Surgery - March 23, 2011
    Niemann
    "Previously, Uruguay had tried to go it alone, but high mortality rates soon caused doctors to shut the program down. After their initial visit, the UCSF transplant team, including anesthesiologist Claus U. Niemann, MD (pictured first), and surgeons Ryutaro Hirose, MD (pictured second), and Peter Stock, MD, PhD, (pictured third) continued to consult with the team in Uruguay, guiding them through everything from patient selection procedures to the use of immunosuppressive medications [...]

  • Kidney Transplants Found Safe in HIV Patients

    UCSF Transplant Surgery - November 18, 2010
    "People infected with the AIDS virus can safely receive a kidney transplant, researchers reported on Wednesday. The finding, published in Thursday's New England Journal of Medicine, is good news for people with HIV who are more prone to kidney disease, in part because of the drugs they must take to stay healthy. Before drug cocktails turned HIV from a death sentence to a chronic condition, patients were not eligible to receive a kidney. But now they can. 'Patient and graft survival are really [...]

  • Improving the Outlook for Simultaneous Pancreas-Kidney Transplants

    UCSF Transplant Surgery - February 01, 2005
    "The body's rejection of transplanted organs and tissues is an unfortunate risk of transplant surgery. Historically, rejection rates in a simultaneous pancreas-kidney (SPK) transplant have been as high as 80% and, in 2001, averaged nearly 20%. ........Diabetes Center surgeons Peter Stock, (left) and Chris Freise (right) have been pioneering new methods of immunosuppression for SPK transplants that do not rely upon steroids, with great success...... " Read Full Diabetes Center [...]

 

 
Site Directory
    X